Premarket Movers | Ares Management Jumps over 8% on S&P 500 Inclusion; Wave Life Sciences Rises Another 4%; WBD Pops Nearly 2%

Tiger Newspress
Dec 09

Shares of Ares Management jumped over 8% in premarket trading. Ares Management will join the S&P 500 before market open on December 11, S&P Dow Jones Indices said on Monday, becoming the latest alternative asset manager to join the benchmark index.

The company will replace Pringles-maker Kellanova in the S&P 500, which is set to be acquired by candy and snacks giant Mars in a $36 billion deal.

Wave Life Sciences rose another 4% after surging 147% on Monday. Wave Life Sciences reported interim Phase 1 data showing that a single 240 mg dose of its investigational obesity therapy WVE-007 reduced visceral fat by 9.4% and total fat by 4.5% at three months, while increasing lean mass by 3.2%.

The placebo group showed no meaningful changes. The drug also produced sustained reductions of over 75% in serum Activin E and was generally safe and well-tolerated up to 600 mg. Wave plans to release additional three- and six-month follow-ups across dosing cohorts through mid-2026 as it prepares for Phase 2 studies.

Shares of WBD rose 1.9% in premarket trading. Paramount Skydance on Monday launched a hostile bid worth $108.4 billion for Warner Bros Discovery, throwing a wrench into the deal with Netflix in a last-ditch effort to create a media powerhouse that would challenge the dominance of the streaming giant.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10